Agios Pharmaceuticals vs Nektar Therapeutics
Nektar Therapeutics reported revenue of $55 million in fiscal 2025, about the same as Agios Pharmaceuticals' $54 million in fiscal 2025. Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Nektar Therapeutics' fell 43.9%. Agios Pharmaceuticals had an operating margin of -873.9%, against -253.7% at Nektar Therapeutics. Free cash flow was −$377 million at Agios Pharmaceuticals and −$209 million at Nektar Therapeutics.
Side by side
| Agios Pharmaceuticals | Nektar Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $54M | $55M |
| Revenue growth | 48.0% | −43.9% |
| Revenue growth a year, last 5 years | — | −18.4% |
| Gross margin | 88.3% | 100.0% |
| Operating margin | −873.9% | −253.7% |
| Net margin | −764.0% | −297.1% |
| Free cash flow | −$377M | −$209M |
| Free cash flow margin | −698.3% | −377.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 0.1% | 23.1% |
| Last close | $31.59 | $37.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $4.3 million | sold $2.4 million |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Agios PharmaceuticalsNektar Therapeutics
Operating margin
Percent of revenue
Agios PharmaceuticalsNektar Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsNektar Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Nektar Therapeutics pages.